Real-time DNA test during brain surgery could help remove more cancer

NCT ID NCT07219199

Not yet recruiting Diagnosis Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a fast genetic test (UR-ddPCR) that checks for IDH1-mutant tumor cells in brain tissue during surgery. If the test finds leftover cancer, the surgeon can remove more tissue right away. The trial will enroll 105 adults with newly diagnosed IDH-mutant glioma at NYU Langone Health. The goal is to see if this approach improves how long patients live without their cancer progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UR-ddPCR assay (a rapid genetic test)
What this could lead to: If successful, this test could help surgeons remove more tumor during surgery, potentially delaying cancer progression and improving survival.
What could go wrong: This is an early-stage, single-site study with only 105 participants. The test may not reliably detect all residual tumor cells, and added resection could increase surgical risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

NYU Langone Health

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.